SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: M. Ramle who wrote (957)7/3/1998 6:46:00 AM
From: billy d  Read Replies (1) of 10280
 
Innitially I was a bit concerned as to the ability of SEPR to get XopeneX off the ground but after some serious consideration and a little "brain-picking" of my children's pediatrician, I think it will take off quite rapidly.

First, the pediatrician I spoke with claims that although steroids have gained a bit more acceptence, they are without a doubt a later alternative to albuterol. With XopeneX showing less side effects and no decrease in lung function it basically makes it a no-brainer for this pediatrician to prescribe.

As far as HMO's go I do agree that they will HAVE to cover this drug as it is far superior to standard albuterol and will be demanded by Dr's as well as informed asthmatics. My son being asthmatic I would not accept Proventil with this drug now available to him.

Lastly, IMO SEPR has been quite thorough in covering all the bases and I believe they are more then ready to sell this product. They have cash,a great science and strong management.

Congrats to the company and all share holders!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News